A new monitoring protocol using troponin and CRP provides guidance on continuing or ceasing clozapine in patients at risk for clozapine-induced myocarditis.
Answers are grounded in this paper and cite their sources.
May support clozapine continuation with troponin/CRP monitoring in mild myocarditis; hypothesis-generating, needs prospective validation before practice change.
This protocol recommends active monitoring for 4 weeks, relying predominantly on troponin and C-reactive protein results. It encourages continuation of clozapine in the presence of mild illness, but defines a threshold for cessation.
No takes yet. Share an insight, caveat, or question.
Ronaldson et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: